Publications

Enayetallah AE, Ziemek D, Leininger MT, Randhawa R, Yang J, Manion TB, Mather DE,…, Greene N, et al. 2011. Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform. PLoS One 6(11):e27009; doi: 10.1371/journal.pone.0027009. PMID: 22073239.

Oller A, Henderson RG. Bioaccessibility testing and its application to read-across for hazard assessment and risk characterisation of metals. Annual Meeting of the Belgian Society for Toxicology and Ecotoxicology (BelTox), 2011.

Robison TW. Toxicology in the nonclinical development of drugs and biologics. Pharmaceutical Education and Research Institute, Genetic Toxicology, Arlington, VA, October 2011.

Tichomirowa MA, Bariler A, Daly AF, Jaffrain-Rea M-L, Ronchi CL, Yaneva M, Urban JD, Petrossians P, et al. 2011. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165(4):509-515; doi: 10.1530/EJE-11-0304. PMID: 21753072.

Lau EC, Mowat FS, Kelsh MA, Legg JC, Engel-Nitz NM, Watson HN, et al. 2011. Use of electronic medical records (EMR) for oncology outcomes research: Assessing the comparability of EMR information to patient registry and health claims data. Clin Epidemiol 3(1):259–272; doi: 10.2147/CLEP.S23690. PMID: 22135501.

Thompson CM, Proctor DM, Haws LC, Hebert CD, Grimes SD, Shertzer HG, Kopec AK, Hixon JG, Zacharewski TR, Harris MA. 2011. Investigation of the mode of action underlying the tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium. Toxicol Sci 123(1):58-70; doi: 10.1093/toxsci/kfr164. PMID: 21712504.

Vivanco S. IVAN’s effectiveness in identifying and addressing environmental harms in underserved communities. University of California, Los Angeles Fielding School of Public Health Graduate Seminar, Los Angeles, CA, Fall 2011.

Greene N, Song M. 2011. Predicting in vivo safety characteristics using physicochemical properties and in vitro assays. Fut Med Chem 3(12):1503-1511; doi: 10.4155/fmc.11.89. PMID: 21882943.

Mitchell M, Taylor A, Lowe K, Langeberg W, et al. Prevalence of bone metastases among breast, lung, and prostate cancer patients. Presented at the 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, August 2011.

Jiang X, Knutson K, Zwica L, Lee S-Y, Chen Q, Hong B, Zhong X, Hao W, et al. The University of Michigan Dioxin Exposure Study: Predictors of household dust PCDD, PCDF, and PCB concentrations. Presented at the 32nd International Symposium on Halogenated Persistent Organic Pollutants – Dioxin 2011, Brussels, Belgium, August 2011.

Jiang X, Zwica L, Knutson K, Towey T, Hedgeman E, Franzblau A, Chen Q, Lee S-Y, et al. Measurements of household dust concentrations of PCDDs, PCDFs, and PCBs from a community in Michigan, USA. Presented at the 32nd International Symposium on Halogenated Persistent Organic Pollutants – Dioxin 2011, Brussels, Belgium, August 2011.

Diliberto JJ, Sirinek L, Burkhalter B, Wikoff DS, Hixon G, Becker J, Patterson DG, Turner W, Tachovsky JA, Birnbaum LS, Haws LC. Endometriosis in a cohort of women living in the Kanawha River Valley in West Virginia: Blood levels of non-dioxin-like PCBs and relationship with BMI and age. Presented at Dioxin 2011, Brussels, Belgium, August 2011.

Haws LC, DeVito MJ, Walker NJ,Harris MA, Tachovsky JA, Birnbaum LS, Farland WH, Wikoff DS. Development of a consensus-based weighting framework for evaluating estimates of relative potency for dioxin-like compounds that includes consideration of data from human cells. Presented at Dioxin 2011, Brussels, Belgium, August 2011.

Haws LC, Fitzgerald L, Burkhalter B, Harris M, Wikoff DS. Assessment of the US EPA’s proposed toxicological values for TCDD for regulation of dioxin-like compounds in foods: Bridging the science divide in a global market. Presented at Dioxin 2011, Brussels, Belgium, August 2011.

Thomas RS, Rowlands JC, Budinsky RA, Thompson CM, Urban JD, Dombkowski, A. 2011. Genomic approaches for relative potency assessment. Presented at Dioxin 2011, Brussels, Belgium, August 2011.

Wikoff DS, Thompson C, Walker N, DeVito M, Harris M, Birnbaum L, Haws L. Derivation of relative potency estimates using benchmark dose modeling: A case study with TCDF. Presented at Dioxin 2011, Brussels, Belgium, August 2011.

Gujral JS, Proctor DM, Su SH, Fedoruk JM. 2011. Water adherence factors for human skin. Risk Anal 31(8):1271-1280; doi: 10.1111/j.1539-6924.2011.01601.x. PMID: 21453376.

Sheehan PJ, Brorby GP, Berman DW, Bogen KT, Holm SE. 2011. Chamber for testing asbestos-containing products: Validation and testing of a re-created chrysotile-containing joint compound.  Ann Occup Hyg 55(7):797-809; doi: 10.1093/annhyg/mer048. PMID: 21795244.

Mitchell M, Taylor A, Lowe K, Langeberg W, Alexander D, Kelsh M, et al. Prevalence of bone metastasis after breast, lung, and prostate cancers: A systematic and quantitative review of the literature. Presented at the 27th Annual Meetings of International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, August 14–17, 2011.

Lau EC, Steffey D, Legg JC, Watson HN, Mowat FS, Kelsh MA. The problem of missing data: Using imputation methods to facilitate oncology outcomes research. Presented at the 27th Annual Meetings of International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, August 14–17, 2011.